| Ashwin M Kansagra, MD | |
|
595 Division St, Elizabeth, NJ 07201-2038 | |
| (615) 778-4066 | |
| Not Available |
| Full Name | Ashwin M Kansagra |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 595 Division St, Elizabeth, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508984519 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 25MA06848900 (New Jersey) | Primary |
| Entity Name | American Current Care Of New Jersey Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609044999 PECOS PAC ID: 1153461264 Enrollment ID: O20091222000279 |
News Archive
A look at how the brain processes information finds a distinct pattern in children with autism spectrum disorders. Using EEGs to track the brain's electrical cross-talk, researchers from Boston Children's Hospital have found a structural difference in brain connections. Compared with neurotypical children, those with autism have multiple redundant connections between neighboring brain areas at the expense of long-distance links.
New guidelines on diagnosis and management of food allergy issued by the National Institute of Allergy and Infectious Diseases a part of NIH, supports a broader use of blood test to improve current clinical practice. Phadia's ImmunoCAP is recognized for its superior predictive values compared to other systems. It provides precise, quantitative and standardized results and help doctors make an accurate diagnosis.
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
A growing understanding of the highly "plastic," changeable nature of the brain-from the level of DNA, proteins, neuronal connections and networks, up to communication across brain regions-is driving the development of new therapeutic approaches to treat chronic pain, stroke, Parkinson's disease, and a variety of other disorders described in an article in Alternative and Complementary Therapies, a journal from Mary Ann Liebert, Inc., publishers.
New surveys show public confusion persists over many health law provisions, including the role of health insurance exchanges which open for enrollment Tuesday, and the financial assistance that will be available to many people to help them buy coverage.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ashwin M Kansagra, MD 720 Cool Springs Blvd, Suite 300, Franklin, TN 37067-2626 Ph: (615) 778-4066 | Ashwin M Kansagra, MD 595 Division St, Elizabeth, NJ 07201-2038 Ph: (615) 778-4066 |
News Archive
A look at how the brain processes information finds a distinct pattern in children with autism spectrum disorders. Using EEGs to track the brain's electrical cross-talk, researchers from Boston Children's Hospital have found a structural difference in brain connections. Compared with neurotypical children, those with autism have multiple redundant connections between neighboring brain areas at the expense of long-distance links.
New guidelines on diagnosis and management of food allergy issued by the National Institute of Allergy and Infectious Diseases a part of NIH, supports a broader use of blood test to improve current clinical practice. Phadia's ImmunoCAP is recognized for its superior predictive values compared to other systems. It provides precise, quantitative and standardized results and help doctors make an accurate diagnosis.
ACT Biotech Inc., a privately held biotechnology company based in San Francisco, California, today announced positive interim data from a Phase 2 trial of the Company's lead oral kinase inhibitor, Telatinib, for the first-line treatment of patients with advanced gastric cancer. This proof-of-concept, multi-center, open label trial was designed to test the efficacy and safety of full-dose Telatinib, administered continuously, as a first-line treatment in combination with a standard regimen of capecitabine and cisplatin in US and European patients.
A growing understanding of the highly "plastic," changeable nature of the brain-from the level of DNA, proteins, neuronal connections and networks, up to communication across brain regions-is driving the development of new therapeutic approaches to treat chronic pain, stroke, Parkinson's disease, and a variety of other disorders described in an article in Alternative and Complementary Therapies, a journal from Mary Ann Liebert, Inc., publishers.
New surveys show public confusion persists over many health law provisions, including the role of health insurance exchanges which open for enrollment Tuesday, and the financial assistance that will be available to many people to help them buy coverage.
› Verified 3 days ago